Regular Aspirin Use Reduces the Risk for Prostate Cancer Death.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 87
- Publication type:
- Article
Works matching IS 21660166 AND DT 2016 AND VI 5 AND IP 2
Results: 19
1
2
The Wide Range of Topics Under the Personalized Care Umbrella.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 60
- By:
- Publication type:
- Article
3
Cabozantinib Improves Standard of Care for Second-Line Treatment of Advanced Kidney Cancer.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 86
- By:
- Publication type:
- Article
4
Regulation and Reimbursement Policies Will Determine the PMI's Legacy.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 94
- By:
- Publication type:
- Article
5
First-in-Human CAR T-Cell Trial Shows Activity in Multiple Myeloma.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 93
- By:
- Publication type:
- Article
6
Benefit for T-DM1 Confirmed.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 91
- Publication type:
- Article
7
Adjuvant Chemoradiotherapy May Provide Benefit in Locally Advanced Bladder Cancer.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 88
- Publication type:
- Article
8
Tamoxifen or Anastrozole for DCIS? Age and Symptom Profiles Matter.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 90
- By:
- Publication type:
- Article
9
Checkpoint Inhibitors Active in Gastric and Esophageal Cancers.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 80
- Publication type:
- Article
10
Immunotherapies in Development for Pancreatic Cancer.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 76
- Publication type:
- Article
11
Reirradiation of Pelvic Area Is Safe and Improves Quality of Life.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 85
- Publication type:
- Article
12
No Benefit from Nephrectomy in High-Risk RCC with Thrombus.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 83
- By:
- Publication type:
- Article
13
PD-L1 Inhibitor Has Strong Showing in Metastatic Urothelial Cancer.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 82
- Publication type:
- Article
14
Biomarker Panel Warrants More Study as Aid to Early CRC Detection.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 81
- Publication type:
- Article
15
Case: Biomarkers in Multiple Myeloma.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 74
- By:
- Publication type:
- Article
16
The Evolving Phenotype of Li-Fraumeni Syndrome.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 72
- By:
- Publication type:
- Article
17
A Century of Medical Product Regulation: The Historic Framework for Personalized Medicine in Oncology.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 66
- By:
- Publication type:
- Article
18
AGENDA.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 65
- Publication type:
- Article
19
Personalizing Oncology Care and the Quest for Companion Diagnostics: A Researcher's Perspective.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 61
- Publication type:
- Article